Cargando…

Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

PURPOSE: This study aims to investigate the feasibility of contouring target volume according to residual tumor and decreasing the dose to the tumor regression field after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: From August 2009 t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Wu, Zheng, Xie, Dehuan, Zeng, Ruifang, Cheng, Wanqin, Hu, Jiang, Huang, Shaomin, Zhou, Shu, Zhong, Rui, Su, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473261/
https://www.ncbi.nlm.nih.gov/pubmed/30121968
http://dx.doi.org/10.4143/crt.2018.250
_version_ 1783412389559926784
author Wang, Lei
Wu, Zheng
Xie, Dehuan
Zeng, Ruifang
Cheng, Wanqin
Hu, Jiang
Huang, Shaomin
Zhou, Shu
Zhong, Rui
Su, Yong
author_facet Wang, Lei
Wu, Zheng
Xie, Dehuan
Zeng, Ruifang
Cheng, Wanqin
Hu, Jiang
Huang, Shaomin
Zhou, Shu
Zhong, Rui
Su, Yong
author_sort Wang, Lei
collection PubMed
description PURPOSE: This study aims to investigate the feasibility of contouring target volume according to residual tumor and decreasing the dose to the tumor regression field after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: From August 2009 to August 2013, patients with stage III–IVB NPC were treated with IC and concurrent chemoradiotherapy. Gross tumor volume of nasopharynx (GTVnx)–residual and gross tumor volume of cervical lymph node (GTVnd)–residual were contoured according to post-IC residual primary tumor and any N+ disease, respectively. The tumor regression field was included in CTVnx1/CTVnd1 and prescribed a dose of 60 Gy. Outcomes and toxicities of all patients were evaluated. RESULTS: A total of 57 patients were enrolled. At a median follow-up of 68 months, three cases displayed locoregional recurrence and one case showed both distant metastasis and locoregional recurrence. All locoregional recurrences were in the GTVnx-residual/GTVnd-residual and in-field. The 5-year overall, locoregional relapse-free, distant metastasis-free, and progression-free survival rates were 82.2%, 87.7%, 85.8% and 80.3%, respectively. CONCLUSION: After IC, contouring of GTVnx-residual/GTVnd-residual as residual tumor volume and distribution 60 Gy ofradiation dose to the tumorregression field may be feasible and need further investigation.
format Online
Article
Text
id pubmed-6473261
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-64732612019-04-26 Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Wang, Lei Wu, Zheng Xie, Dehuan Zeng, Ruifang Cheng, Wanqin Hu, Jiang Huang, Shaomin Zhou, Shu Zhong, Rui Su, Yong Cancer Res Treat Original Article PURPOSE: This study aims to investigate the feasibility of contouring target volume according to residual tumor and decreasing the dose to the tumor regression field after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: From August 2009 to August 2013, patients with stage III–IVB NPC were treated with IC and concurrent chemoradiotherapy. Gross tumor volume of nasopharynx (GTVnx)–residual and gross tumor volume of cervical lymph node (GTVnd)–residual were contoured according to post-IC residual primary tumor and any N+ disease, respectively. The tumor regression field was included in CTVnx1/CTVnd1 and prescribed a dose of 60 Gy. Outcomes and toxicities of all patients were evaluated. RESULTS: A total of 57 patients were enrolled. At a median follow-up of 68 months, three cases displayed locoregional recurrence and one case showed both distant metastasis and locoregional recurrence. All locoregional recurrences were in the GTVnx-residual/GTVnd-residual and in-field. The 5-year overall, locoregional relapse-free, distant metastasis-free, and progression-free survival rates were 82.2%, 87.7%, 85.8% and 80.3%, respectively. CONCLUSION: After IC, contouring of GTVnx-residual/GTVnd-residual as residual tumor volume and distribution 60 Gy ofradiation dose to the tumorregression field may be feasible and need further investigation. Korean Cancer Association 2019-04 2018-08-13 /pmc/articles/PMC6473261/ /pubmed/30121968 http://dx.doi.org/10.4143/crt.2018.250 Text en Copyright © 2019 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Wang, Lei
Wu, Zheng
Xie, Dehuan
Zeng, Ruifang
Cheng, Wanqin
Hu, Jiang
Huang, Shaomin
Zhou, Shu
Zhong, Rui
Su, Yong
Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
title Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
title_full Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
title_fullStr Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
title_full_unstemmed Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
title_short Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
title_sort reduction of target volume and the corresponding dose for the tumor regression field after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473261/
https://www.ncbi.nlm.nih.gov/pubmed/30121968
http://dx.doi.org/10.4143/crt.2018.250
work_keys_str_mv AT wanglei reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma
AT wuzheng reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma
AT xiedehuan reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma
AT zengruifang reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma
AT chengwanqin reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma
AT hujiang reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma
AT huangshaomin reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma
AT zhoushu reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma
AT zhongrui reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma
AT suyong reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma